0001079973-23-001741.txt : 20231213 0001079973-23-001741.hdr.sgml : 20231213 20231213080008 ACCESSION NUMBER: 0001079973-23-001741 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231213 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231213 DATE AS OF CHANGE: 20231213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nemaura Medical Inc. CENTRAL INDEX KEY: 0001602078 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 465027260 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38355 FILM NUMBER: 231482994 BUSINESS ADDRESS: STREET 1: 57 WEST 57TH STREET CITY: MANHATTAN STATE: NY ZIP: 10019 BUSINESS PHONE: 44-1509-222-912 MAIL ADDRESS: STREET 1: 57 WEST 57TH STREET CITY: MANHATTAN STATE: NY ZIP: 10019 8-K 1 nmra_8k.htm FORM 8-K

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934

Date of Report (Date of earliest event reported): December 13, 2023

NEMAURA MEDICAL INC.

(Exact name of registrant as specified in charter)

Nevada

(State or other jurisdiction of incorporation)

001-38355		46-5027260
(Commission File Number)		(IRS Employer Identification No.)

57 West 57th Street Manhattan, NY		10019
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code:		+1 (646) 416-8000
N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	NMRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On December 13, 2023, Nemaura Medical Inc. (the “Company”) issued a press release announcing that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information included in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The information set forth under this Item 7.01 shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

99.1		Press release issued by the registrant on December 13, 2023.
104		Cover Page Interactive Data File - the cover page XBRL tags are embedded with the Inline XBRL document

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEMAURA MEDICAL INC.

	By:	/s/ Dewan F.H. Chowdhury
		Dewan F.H. Chowdhury Chief Executive Officer

Date: December 13, 2023

EX-99.1 2 ex99x1.htm EXHIBIT 99.1

Exhibit 99.1

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

Loughborough, UK, December 13, 2023 (GLOBE NEWSWIRE) – Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1^st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel’s decision.

About Nemaura Medical, Inc.

Nemaura Medical, Inc. is a medical technology company developing and wearable diagnostic devices. The company is currently commercializing sugarBEAT^® and proBEAT^™. sugarBEAT^®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura Medical has submitted a proposal for a Modular PMA (Premarket Approval Application) application for sugarBEAT^® to the U.S. FDA, for its generation II, 24 hour sensor. proBEAT^™ is a non-regulated version of sugarBEAT which combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT^®diabetes program.

Additionally, Nemaura Medical launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura Medical believes that up to half the population could benefit from a sensor and program that monitors metabolic health and well-being.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit www.NemauraMedical.com.

Cautionary Statement Regarding Forward-Looking Statements:

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT^™ in the U.S., risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura Medical’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura Medical and its partners’ ability to develop, market and sell proBEAT^™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT^™ digital health, and sugarBEAT^®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The U.S. Food and Drug Administration (the “FDA”) reserves the right to re-evaluate its decision that proBEAT^™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura Medical’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K, each as may be amended from time to time. Nemaura Medical undertakes no obligation to publicly update or revise any forward-looking statements.

Investor Relations Contact:

IR@NemauraMedical.com

EX-101.SCH 3 nmra-20231213.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 nmra-20231213_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 nmra-20231213_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 13, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 13, 2023
Entity File Number	001-38355
Entity Registrant Name	NEMAURA MEDICAL INC.
Entity Central Index Key	0001602078
Entity Tax Identification Number	46-5027260
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	57 West 57th Street
Entity Address, City or Town	Manhattan
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	(646)
Local Phone Number	416-8000
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock
Trading Symbol	NMRD
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 7 nmra_8k_htm.xml IDEA: XBRL DOCUMENT 0001602078 2023-12-13 2023-12-13 iso4217:USD shares iso4217:USD shares false 0001602078 8-K 2023-12-13 NEMAURA MEDICAL INC. NV 001-38355 46-5027260 57 West 57th Street Manhattan NY 10019 (646) 416-8000 false false false false Common Stock NMRD NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nemauramedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nmra-20231213.xsd nmra-20231213_lab.xml nmra-20231213_pre.xml nmra_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "nmra_8k.htm": { "nsprefix": "NMRA", "nsuri": "http://nemauramedical.com/20231213", "dts": { "schema": { "local": [ "nmra-20231213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nmra-20231213_lab.xml" ] }, "presentationLink": { "local": [ "nmra-20231213_pre.xml" ] }, "inline": { "local": [ "nmra_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://nemauramedical.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "nmra_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "nmra_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://nemauramedical.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001079973-23-001741-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-23-001741-xbrl.zip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